Head-to-head evidence
Camrelizumab vs Serplulimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Camrelizumab
Developed by Jiangsu Hengrui Pharmaceuticals
NCT03134872 · Phase 3 · completed
The study randomly assigned 419 participants to treatment or an active chemotherapy comparator, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Serplulimab
Developed by Shanghai Henlius Biotech
NCT05807893 · Phase 2/3 · completed
The study treated 40 participants in a non-randomized, open-label, single-arm design without a comparator group. Its primary endpoint was intracranial progression-free survival. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: October 2026 · NCT06848699 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camrelizumab's landscape · Serplulimab's landscape